Testing The Addition Of Nivolumab To Chemotherapy In Treatment Of Soft Tissue Sarcoma
To compare treatment with chemotherapy (paclitaxel) alone to using a combination of nivolumab plus chemotherapy (paclitaxel) treatment in patients with angiosarcoma who have not been treated with paclitaxel chemotherapy alone.
DiagnosisPatient has a type of cancer called angiosarcoma
Cutaneous or visceral angiosarcoma
No prior PD-1, or VEGF TKI, PS 0-1
Patients must sign an approved informed consent and authorization permitting release of personal health information.
- Group 1: In Arm 1, participants will receive combination of paclitaxel and nivolumab. Participants assigned to Arm 2, will only receive paclitaxel.
- Group 2: Patients who have been treated with "taxane" chemotherapy. In this group, participants will receive a combination of cabozantinib and nivolumab.
For more information, visit ClinicalTrials.gov